TG Therapeutics Announces Final Results of the GENUINE Phase 3 Study Evaluating Ublituximab plus Ibrutinib in Previously Treated High-Risk Chronic Lymphocytic Leukemia at the 56th American Society of Clinical Oncology Annual Meeting

NEXT STORY
TRACON Pharmaceuticals Highlights Updated Envafolimab Results in MSI-H/dMMR Colorectal Cancer and Results from Clinical Trial of Opdivo and Yervoy Combination Therapy in Undifferentiated Pleomorphic Sarcoma Conducted by Alliance for Clinical Trials in Oncology
PREV STORY
Turning Point Therapeutics Presents Preclinical Data For Novel RET Inhibitor Candidate, TPX-0046
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

GeoVax and Emory University to Collaborate on HPV Therapeutic Program for Head and Neck Cancers

GeoVax Continues Expansion of its MVA-VLP Vaccine Pipeline with Multiple Collaborations in Infectious Disease and ...

author_avatar
NASDAQ Market News

Mersana Strengthens Board of Directors Leadership with Appointment of Willard H. Dere, M.D., Professor at the University of Utah and Retired Chief Medical Officer of Amgen

CAMBRIDGE, Mass., March 19, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage ...

author_avatar
NASDAQ Market News

BeyondSpring to Present at the Deutsche Bank 43rd Annual Health Care Conference

NEW YORK, May 07, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global, clinical-stage ...

author_avatar
NASDAQ Market News